COMPANY PROFILE

Minerva Biotechnologies

Explore full profile

Minerva Biotechnologies - We See the Future First

Waltham, United StatesFounded 1999Biotech & Life Sciences

Valuation $100–250M Last recorded · 2018

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Minerva Biotechnologies

Minerva Biotechnologies, founded in 1999 and located in Waltham, MA, is a privately held biotech company specializing in cancer therapeutics and regenerative medicine. The company focuses on developing CAR T therapeutics that target solid tumors expressing the MUC1 protein, which is present in approximately 80% of all cancers. Minerva's innovative approach leverages the unique properties of MUC1 to create effective treatments for these cancers.

In addition to cancer therapeutics, Minerva is at the forefront of regenerative medicine. The company utilizes induced pluripotent stem cell (iPSC) technology to enable pharmaceutical companies to develop treatments for a variety of diseases. This technology is more efficient in generating iPSCs, allows for faster cell expansion, and increases differentiation efficiency, making it a valuable tool in the field of regenerative medicine.

Minerva serves pharmaceutical companies and operates in the biotech and healthcare markets. The company's business model involves developing and licensing its proprietary technologies and therapies to pharmaceutical partners, generating revenue through licensing fees, milestone payments, and royalties on sales of products developed using its technologies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 1999
Headquarters: Waltham, United States
Employees: 18
Open positions: 1
Dealroom signal: 42.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Jan 2022	$24M	$96M	Undisclosed	—
EARLY VCOther financing	Oct 2018	$29M	$116M	Undisclosed	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Minerva Biotechnologies website traffic

Latest recorded traffic for Minerva Biotechnologies is 3.8K monthly website visits, up 72.7% over the last three months. Minerva Biotechnologies's team grew 0% over the past year.

Latest monthly visits3.8K 3-month web change+72.7% 1-year team growth0%

Monthly website visitsJan 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Research Associate (Chemistry)Woburn, MA · Other · Jul 2, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BRBryleosAdvancing treatment of chronic diseases through early-stage proteomic and metabolomic data analysis	Johnson City, United States	Operational	9	$5.1M	$25M
ETEngimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies	Allschwil, Switzerland	Operational
KBKactus BiosystemsA biotech company focusing on research and development of targeted protein tools	Cambridge, United States	Operational
BTBAKX TherapeuticsWe create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations	Kingston, United States	Closed
DIDIADEMImproves clinicians/patient understanding about risk of Dementia/Alzheimer’s to enable earlier decisions and outcome	London, United Kingdom	Operational
TBTentarix BiotherapeuticsCreates innovative protein therapeutics with uniquely combined bioactivities that leverage powerful synergistic biology	San Diego, United States	Operational
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational
LELeadartisA company developing bispecific tumor targeted antibodies based on its highly innovative protein engineering platform Trimerbody®	Tres Cantos, Spain	Operational